Transmitted extended-spectrum extensively drug-resistant tuberculosis in Beijing, China, with discordant whole-genome sequencing analysis results

Journal of Clinical Microbiology

Volumn 53, Issue 8, 2015, Pages 2781-2784

  Li, Hao ^a   Ur Rehman Kayani, Masood ^b   Gu, Yunting ^b   Wang, Xiaobo ^b   Zhu, Ting ^b   Duan, Hongfei ^b   Ma, Yifeng ^b   Huang, Hairong ^b   Javid, Babak ^a  

^a Tsinghua University   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CASE REPORT; CHINA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; GENE SEQUENCE; HUMAN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT REDUCTION; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; CHEMISTRY; CLASSIFICATION; DNA SEQUENCE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; TRANSMISSION;

ADULT; ANTITUBERCULAR AGENTS; BEIJING; DNA, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOME, BACTERIAL; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84938062548     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00891-15     Document Type: Article

References (19)

1. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Wholegenome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290-292. http://dx.doi.org/10.1056/NEJMc1215305.
2. Toosky M, Javid B. 2014. Novel diagnostics and therapeutics for drugresistant tuberculosis. Br Med Bull 110:129-140. http://dx.doi.org/10.1093/bmb/ldu011.
3. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. 2007. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 12: E070517.1. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId -3194.
4. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420-425. http://dx.doi.org/10.1378/chest.08-2427.
5. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2012. Totally drugresistant tuberculosis in India. Clin Infect Dis 54:579-581. http://dx.doi.org/10.1093/cid/cir889.
6. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Muller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, David van Helden P, Victor TC, Trollip AP. 2013. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 19:449-455. http://dx.doi.org/10.3201/eid1903.120246.
7. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 2007. 125 years after Robert Koch?s discovery of the tubercle bacillus: the new XDR-TB threat. Is ?science? enough to tackle the epidemic? Eur Respir J 29:423-427. http://dx.doi.org/10.1183/09031936.00001307.
8. Velayati AA, Farnia P, Merza MA, Zhavnerko GK, Tabarsi P, Titov LP, Ghanavei J, Farnia P, Setare M, Poleschuyk NN, Owlia P, Sheikolslami M, Ranjbar R, Masjedi MR. 2010. New insight into extremely drugresistant tuberculosis: using atomic force microscopy. Eur Respir J 36: 1490-1493. http://dx.doi.org/10.1183/09031936.00064510.
9. Farnia P, Mohammad RM, Merza MA, Tabarsi P, Zhavnerko GK, Ibrahim TA, Kuan HO, Ghanavei J, Farnia P, Ranjbar R, Poleschuyk NN, Titov LP, Owlia P, Kazampour M, Setareh M, Sheikolslami M, Migliori GB, Velayati AA. 2010. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. Int J Clin Exp Med 3:308-314.
10. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis.NEngl J Med 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
11. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371: 723-732. http://dx.doi.org/10.1056/NEJMoa1313865.
12. Gagneux S. 2009. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 15(Suppl 1):S66-S68.
13. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550-10.
14. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F. 2012. Microevolution of extensively drugresistant tuberculosis in Russia. Genome Res 22:735-745. http://dx.doi.org/10.1101/gr.128678.111.
15. Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE, III, Alland D. 2015. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43-51. http://dx.doi.org/10.1128/JCM.02059-14.
16. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53:5064-5068. http://dx.doi.org/10.1128/AAC.00851-09.
17. Zhang Z, Liu M, Wang Y, Pang Y, Kam KM, Zhao Y. 2014. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis 33:1959-1966. http://dx.doi.org/10.1007/s10096-014-2144-5.
18. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 26:874-877. http://dx.doi.org/10.1086/513945.
19. Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME. 2015. Drug-resistance mechanisms and tuberculosis drugs. Lancet 385:305-307. http://dx.doi.org/10.1016/S0140-6736(14)62450-8.